Syndax Pharmaceuticals is a company.
Syndax Pharmaceuticals has raised $156.0M across 4 funding rounds.
Key people at Syndax Pharmaceuticals.
Syndax Pharmaceuticals has raised $156.0M in total across 4 funding rounds.
Syndax Pharmaceuticals (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company focused on developing innovative cancer therapies, particularly first-in-class treatments for areas like acute leukemia and chronic graft-versus-host disease.[1][2][3] Its pipeline features key assets such as a menin inhibitor for relapsed/refractory acute leukemia and a monoclonal antibody targeting the CSF-1 receptor.[1][3] Headquartered in New York with 280 employees, Syndax serves patients with serious cancers by addressing unmet needs through clinical trials and commercialization efforts, demonstrating growth via an expanding oncology portfolio.[1]
Syndax Pharmaceuticals emerged as a precision oncology player, evolving from a clinical-stage entity to a commercial-stage innovator dedicated to cancer therapies.[1][2][3] While specific founder details are not detailed in available sources, the company has built traction through pivotal pipeline advancements, including menin inhibitors and CSF-1R antibodies, marking key moments in targeting relapsed/refractory acute leukemia and chronic conditions.[1][3] Its public listing on NASDAQ (SNDX) underscores early momentum in biopharma, with a New York HQ supporting ongoing expansion.[1][2]
Syndax rides the wave of precision oncology trends, capitalizing on advances in targeted therapies for genetically defined cancers like acute leukemia amid rising demand for personalized treatments.[1][3] Timing aligns with a biopharma shift toward commercial-stage innovators addressing unmet needs in hematologic malignancies, bolstered by market forces such as aging populations, immunotherapy evolution, and investor interest in late-stage assets.[2] By influencing the ecosystem through clinical trials and potential blockbusters, Syndax contributes to redefining cancer care standards, fostering competition and collaboration in oncology pipelines.[1][3]
Syndax is poised for milestone-driven growth, with ongoing trials potentially yielding approvals for its menin inhibitor and CSF-1R antibody, expanding into broader leukemia and chronic disease markets.[1][3] Trends like AI-enhanced drug discovery and combination therapies will shape its path, amplifying influence as a commercial oncology leader. As a pipeline innovator, Syndax exemplifies biopharma's push to transform cancer outcomes, building on its commitment to unmet needs for sustained impact.[1][2][3]
Syndax Pharmaceuticals has raised $156.0M in total across 4 funding rounds.
Syndax Pharmaceuticals's investors include aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital.
Key people at Syndax Pharmaceuticals.
Syndax Pharmaceuticals has raised $156.0M across 4 funding rounds. Most recently, it raised $80.0M Series C in August 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2015 | $80.0M Series C | aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital | |
| Aug 1, 2013 | $27.0M Series B | aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital | |
| Mar 1, 2010 | $9.0M Series A | aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital | |
| Apr 1, 2007 | $40.0M Series A | aMoon Fund, Domain Associates, InterWest, Osage University Partners, T1D Fund, Vivo Capital |
